Refine by
Solid Tumors Articles & Analysis
49 articles found
Alfa Cytology is continuously expanding its expertise into multifaceted aspects of oncology, including solid tumors, blood cancers, and rare cancer syndromes. About Alfa CytologyAlfa Cytology is a biotechnology leader focused on pioneering cancer basic research services. ...
ESMO updated its recommendations for NGS in advanced cancers this year, urging broader use of NGS in additional cancer types and the inclusion of tumor-agnostic biomarkers. The ESMO Precision Medicine Working Group (PMWG) first published its recommendations for when to use next-generation sequencing (NGS) in routine practice for patients with metastatic cancers in 20201. At that time, based ...
Alfa Cytology, a biotech company composed of scientists, bioinformatics, and oncologists, has recently announced its pancreatic cancer vaccine development services to provide further strategies for cancer therapy research. Compared to other solid tumors, pancreatic cancer (PC) lacks effective therapy with poor outcomes. ...
Dr. Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. Funda Meric-Bernstam, and Dr. Kellogg Parsons. The oncology field is rapidly advancing with the development of antibody-drug conjugates (ADCs), offering new hope for ...
ByTempus
Antibodies are relatively effective for hematologic malignancies. For solid tumors, using small-sized antibodies (such as single-domain antibodies or scFv) and peptide-conjugated radiopharmaceuticals has become a prominent direction in research and development due to their small size and excellent tissue penetration capabilities. ...
Because nanobodies are smaller in size and have stronger tumor tissue penetration capabilities, researchers are currently applying them to ADC drugs for the treatment of solid tumors, hoping to improve the solid tumor tissue penetration effects of current ADC drugs.Nanobody StructureGenerally, the relative ...
The catabolism of this structure causes Lys-SMC-DM1 to become the main tumor metabolite. Furthermore, drugs linked to this linker usually cannot exert bystander effect because the released catabolites are less permeable. ...
NIR-PIT drugs can form a new targeted anti-tumor platform that irradiates infrared light to the tumor site through the device. ...
The high specificity of bispecific antibodies enables more precise targeting of tumor cells. On the other hand, promoting the coordinated endocytosis of the two targets through cross-linking can improve the efficiency of toxins entering tumor cells. ...
CD73 Expression and Its Impact on Tumor Cells CD73 is found at higher expression levels in the majority of human solid tumors, and its presence is closely linked to tumor invasiveness and metastasis[15]. Research[16] has confirmed that the extracellular adenosine produced by CD73 on tumor cells plays a ...
In addition, Trop-2 is highly expressed in tumors and is associated with poor tumor prognosis. These characteristics all indicate that Trop-2 will become a good target for tumor treatment. ...
In particular, linker design plays a key role in regulating ADC stability in systemic circulation and payload release efficiency in tumors, thereby affecting ADC pharmacokinetics (PK), efficacy, and toxicity profiles. ...
Consequently, WES has become the preferred approach for comparing tumor-normal samples. Tumor Mutational Burden (TMB) Analysis using WES Tumor Mutational Burden (TMB) quantifies the number of somatic mutations per megabase (MB) of the longest transcript sequence. Although TMB shows potential as a biomarker for immunotherapy in ...
Preclinical data suggest that the anticancer activity of Enfortumab Vedotin is attributed to its binding to cells expressing Nectin-4, followed by internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell. This is believed to inhibit cell proliferation (cell cycle arrest) and induce programmed cell death (apoptosis). ...
TSLP and TH2 In allergic inflammation, TSLP can strongly activate DCs (dendritic cells), which subsequently drive the development of naive TH cells into "inflammatory" effector TH2 cells that express classical TH2 cytokines, pro-inflammatory tumor necrosis factor-alpha (TNF-α), and anti-inflammatory IL-10. ...
Tumors and Blood Vessel Growth Tumor, as an abnormal mass of cells, has blood vessels of various sizes that can be seen everywhere on the surface and deep within it. ...
Currently, 9 ADCs have been approved, of which 5 are used for hematoma and 4 for solid tumor treatment. After more than 20 years of development, ADC biopharmaceuticals are becoming the main force in the treatment of cancer. ...
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. ...
In addition, if the size of the antibody part is smaller and the binding force is higher, the drug molecules can penetrate into the solid tumor better, such as a new class of DARPin (designed ankyrin repeat proteins)-toxin-conjugated drugs. ...
CAR T cell therapy has had tremendous success for certain cancer types, such as leukaemia. However, solid tumors have been more difficult to address with this approach, as tumor cells have found ways to evade CAR T cell functions as well, making the therapy less effective and less durable. ...